Welcome to our dedicated page for BECTON DICKINSON & CO SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Becton, Dickinson and Company filings document the reporting, governance and capital-structure matters of a New York Stock Exchange-listed medical technology issuer. Its Form 8-K disclosures cover quarterly operating results, non-GAAP financial measures, dividend and capital allocation updates, executive appointments, compensatory arrangements and amendments to corporate by-laws.
The filing record also documents BD's completed separation of its Biosciences and Diagnostic Solutions business and related recast historical financial information presenting that business as discontinued operations. Capital-structure disclosures include registered common stock, NYSE-listed notes and tender-offer activity involving senior notes and debentures.
Becton Dickinson & Co executive Michael Feld, EVP and Chief Revenue Officer, sold 75 shares of Common Stock on 2026-07-27 at $157.1300 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on February 7, 2025, and Feld now holds 20,934 shares directly.
BDX insider Michael Feld filed notice of a planned sale of common stock. The plan covers 75 shares, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an expected aggregate price of $11,727.00 on or after July 27, 2026 on the NYSE. The shares relate to Restricted Stock Units acquired from the issuer on August 20, 2025. The disclosure also lists prior sales under a Rule 10b5-1 trading plan: 75 shares for $11,460.00 on June 26, 2026 and 75 shares for $11,051.25 on May 26, 2026.
Becton, Dickinson and Company announced that Dr. Michael (Mike) Garrison, executive vice president and president of the Medical Essentials and BioPharma Systems segments, plans to retire after more than 20 years with BD, effective October 2. He will remain in his role through the end of the fiscal year to support a smooth transition. A comprehensive search is underway to identify the next president of the Medical Essentials segment. To streamline the operating model, the BioPharma Systems segment will report directly to Chairman, CEO and President Thomas E. Polen, reflecting its strategic importance as a growth driver.
BD describes itself as one of the world’s largest pure-play medical technology companies, operating globally with more than 60,000 employees and delivering billions of products annually across medical essentials, connected care, biopharma systems and interventional therapies.
Becton Dickinson executive Muhsin Bilal reported routine equity compensation activity. He received 14,342 shares of Common Stock as a restricted stock unit award under the company’s 2004 equity-based compensation plan. In a separate entry, 1,935 shares were withheld to cover taxes upon RSU vesting. After these transactions, he directly holds 41,359 shares of Becton Dickinson common stock.
Becton Dickinson & Co executive Michael Feld reported a small stock sale. On June 26, 2026, the EVP and Chief Revenue Officer sold 75 shares of Common Stock in an open-market transaction at $152.80 per share. After this sale, he directly owns 21,009 shares of the company’s stock.
Becton, Dickinson and Company (BDX) proposed resale notice filed for Common Stock sales by Michael Feld. The filing lists 10b5-1 planned sales of 75 shares on 05/26/2026 at $11,051.25 and 74 shares on 04/27/2026 at $11,243.56. The excerpt also shows 75 Restricted Stock Units with an 08/20/2025 grant date. The filing records the broker as Morgan Stanley Smith Barney LLC.
Becton Dickinson executive Michael David Garrison reported an open-market sale of company stock. On this Form 4, he sold 1,100 shares of Becton Dickinson common stock at a price of $145.66 per share. After the transaction, he directly owns 13,172 shares of common stock.
Becton, Dickinson and Company reported an insider sale. The filing lists a sale of 1,100 shares reported under a 10b5-1 plan with the trade date 06/10/2026. The notice also references Restricted Stock Units dated 04/05/2022.
Becton Dickinson & Co EVP and Chief People Officer Manish Sinha filed an initial Form 3 showing his equity holdings in the company. He directly owns 8,806 shares of common stock, including restricted stock units granted under the company’s 2004 equity-based compensation plan.
He also holds multiple grants of stock appreciation rights tied to common stock, with exercise prices ranging from about $167 to $189 per share and expiration dates between 2027 and 2034. These rights vest in four annual installments starting one year after each grant date.
Becton Dickinson & Co executive Michael David Garrison reported an open-market sale of company stock. On June 10, 2026, he sold 1,100 shares of Common Stock at an average price of $151.48 per share. After this transaction, he directly holds 14,272 shares. A footnote explains that his direct holdings reflect prior adjustments tied to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp., which affected the number of shares underlying previously reported, unvested time-vested restricted stock units.